Discover
Visualize rapid, validated insights through real-world data.
Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion
Over 800,000 abortions occur annually in the United States, the majority of which are ...
Predictions and resolutions for synthetic data
By Dr. Khaled El Emam Posted On: December 21st, 2021
Discover AI publishes 7 key use cases for synthetic data in the pharmaceutical industry
By Replica Analytics staff Posted On: December 16, 2021
Norwegian data protection authority strongly recommends synthetic data for software testing
By Dr. Khaled El Emam Posted On: December 2nd, 2021
Generating Synthetic Longitudinal Data
What industry can learn from RWE demonstration projects
As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
RWE guidance watch: EMA real world evidence guidance on registry-based studies
UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
New Gartner survey suggests synthetic data is the future of data sharing
By Dr. Khaled El Emam Posted On: November 9th, 2021
COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight
Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Synthetic Data Generation for Rare Disease Research
Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health
Understanding how medical interventions impact patients has always been a top priority ...
Measuring Re-identification Risk for Synthetic and Anonymized Data
Ten Recommendations for Regulating Non-identifiable Data
There is considerable activity today in regulatory development and updates around the ...
Synthetic Data
ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology
This year at ICPE All Access, Aetion’s scientific research was represented across ...
Practical Mechanisms for Generating Anonymous Data
Ten Recommendations For Regulating De-identification
ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE
This year at ICPE All Access, Aetion’s scientific research is represented across ...
RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot
In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Could Synthetic Data be the Future of Data Sharing?
This article in CPO Magazine explores the rise of synthetic data generation (SDG) as a ...
Patient voice in RWE: Generating evidence that will impact payer and HTA decision-making
With the rise of patient-centered medicine and accelerated approvals, health technology ...
CDER-Approved NDA for LUMAKRAS™ (sotarasib)
On May 28, 2021, FDA granted Accelerated Approval to Amgen’s LUMAKRAS™ (sotarasib) for ...
CBER-Approved sBLA for KEDRAB® (rabies immune globulin (human))
On May 17, 2021, FDA approved an sBLA for Kamada’s KEDRAB® (rabies immune globulin ...
RWE Guidance Watch: IMPACT HTA publishes recommendations on the use of RWE in HTA
As researchers await comprehensive guidance on the use of real-world evidence (RWE)—and ...